

# Paolo Ferrari

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6998193/publications.pdf>

Version: 2024-02-01

147  
papers

9,078  
citations

57758

44  
h-index

51608

86  
g-index

154  
all docs

154  
docs citations

154  
times ranked

11571  
citing authors

#	ARTICLE	IF	CITATIONS
1	Reply to Gremese etÂal.: Statistical reasoning to evaluate treatment effects when data are collected with lack of design: Covid-19 experience. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2103168119.	7.1	0
2	Poor neutralization and rapid decay of antibodies to SARS-CoV-2 variants in vaccinated dialysis patients. PLoS ONE, 2022, 17, e0263328.	2.5	21
3	Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature, 2022, 602, 664-670.	27.8	917
4	ACE2-binding exposes the SARS-CoV-2 fusion peptide to broadly neutralizing coronavirus antibodies. Science, 2022, 377, 735-742.	12.6	85
5	A data-driven approach to identify risk profiles and protective drugs in COVID-19. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	32
6	Risk assessment and seroprevalence of SARS-CoV-2 infection in healthcare workers of COVID-19 and non-COVID-19 hospitals in Southern Switzerland. Lancet Regional Health - Europe, The, 2021, 1, 100013.	5.6	66
7	Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. Cell, 2021, 184, 1171-1187.e20.	28.9	541
8	Data and optimisation requirements for Kidney Exchange Programs. Health Informatics Journal, 2021, 27, 146045822110099.	2.1	2
9	Clonal analysis of immunodominance and cross-reactivity of the CD4 T cell response to SARS-CoV-2. Science, 2021, 372, 1336-1341.	12.6	108
10	Broad betacoronavirus neutralization by a stem helixâ€specific human antibody. Science, 2021, 373, 1109-1116.	12.6	262
11	Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology. Cell, 2020, 183, 1024-1042.e21.	28.9	1,195
12	Crossing borders to facilitate live donor kidney transplantation: the Czechâ€Austrian kidney paired donation program â€ a retrospective study. Transplant International, 2020, 33, 1199-1210.	1.6	5
13	Utilization of Deceased Donor Kidneys to Initiate Living Donor Chains: Practical, Ethical, and Logistical Issues. Transplantation, 2019, 103, 1988-1989.	1.0	0
14	Pre- and postdonation kidney function in donors of a kidney paired donation with unique criteria for donor glomerular filtration rate - a longitudinal cohort analysis. Transplant International, 2019, 32, 291-299.	1.6	6
15	Early kidney allograft loss-Is there scope for improvement?. Transplant International, 2018, 31, 864-866.	1.6	0
16	Challenges of kidney paired donation transplants involving multiple donor and recipient surgeons across Australia. ANZ Journal of Surgery, 2018, 88, 167-171.	0.7	8
17	Characterization of hepatic and cardiac iron deposition during standard treatment of anaemia in haemodialysis. Nephrology, 2017, 22, 114-117.	1.6	19
18	Providing Better-Matched Donors for HLA Mismatched Compatible Pairs Through Kidney Paired Donation. Transplantation, 2017, 101, 642-648.	1.0	33

#	ARTICLE	IF	CITATIONS
19	Association between serum hepcidin and primary resistance to erythropoiesis-stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial. <i>Nephrology</i> , 2017, 22, 548-554.	1.6	11
20	Diagnosing and preventing iron overload. <i>Hemodialysis International</i> , 2017, 21, S58-S67.	0.9	23
21	Kidney Paired Donation and the "Valuable Consideration" Problem. <i>Transplantation</i> , 2017, 101, 1996-2002.	1.0	5
22	Optimizing Outcomes in Pediatric Renal Transplantation Through the Australian Paired Kidney Exchange Program. <i>American Journal of Transplantation</i> , 2017, 17, 534-541.	4.7	26
23	Waiting Time Between Failure of First Graft and Second Kidney Transplant and Graft and Patient Survival. <i>Transplantation</i> , 2016, 100, 1767-1775.	1.0	27
24	Outcomes of kidney paired donation transplants in relation to shipping and cold ischaemia time. <i>Transplant International</i> , 2016, 29, 425-431.	1.6	20
25	The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial. <i>Redox Report</i> , 2016, 21, 14-23.	4.5	8
26	Nurturing the benefits of pre-emptive kidney transplantation. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 681-682.	0.7	3
27	Four years of experience with the Australian kidney paired donation programme. <i>Nephrology</i> , 2015, 20, 124-131.	1.6	28
28	Association between Serum Alkaline Phosphatase and Primary Resistance to Erythropoiesis Stimulating Agents in Chronic Kidney Disease: A Secondary Analysis of the HERO Trial. <i>Canadian Journal of Kidney Health and Disease</i> , 2015, 2, 66.	1.1	8
29	A Randomized, Placebo-Controlled Trial of Pentoxifylline on Erythropoiesis-Stimulating Agent Hyporesponsiveness in Anemic Patients With CKD: The Handling Erythropoietin Resistance With Oxpentifylline (HERO) Trial. <i>American Journal of Kidney Diseases</i> , 2015, 65, 49-57.	1.9	29
30	Kidney paired donation: principles, protocols and programs. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1276-1285.	0.7	101
31	Kidney paired donation: a plea for a Swiss National Programme. <i>Swiss Medical Weekly</i> , 2015, 145, w14083.	1.6	12
32	Predictors of perioperative blood transfusions in patients with chronic kidney disease undergoing elective knee and hip arthroplasty. <i>Nephrology</i> , 2014, 19, 404-409.	1.6	25
33	Comparison of computer tomographic volumetry versus nuclear split renal function to determine residual renal function after living kidney donation. <i>Acta Radiologica</i> , 2014, 55, 753-760.	1.1	33
34	Acute kidney injury due to decompression illness. <i>CKJ: Clinical Kidney Journal</i> , 2014, 7, 380-382.	2.9	4
35	Modeling the Benefits and Costs of Integrating an Acceptable HLA Mismatch Allocation Model for Highly Sensitized Patients. <i>Transplantation</i> , 2014, 97, 769-774.	1.0	20
36	Peri-operative third party red blood cell transfusion in renal transplantation and the risk of antibody-mediated rejection and graft loss. <i>Transplant Immunology</i> , 2013, 29, 22-27.	1.2	36

#	ARTICLE	IF	CITATIONS
37	Pre-transplant donor specific anti-HLA antibody is associated with antibody-mediated rejection, progressive graft dysfunction and patient death. <i>Transplant Immunology</i> , 2013, 28, 148-153.	1.2	52
38	Transnational validation of the Australian algorithm for virtual crossmatch allocation in kidney paired donation. <i>Human Immunology</i> , 2013, 74, 500-505.	2.4	21
39	Pharmacokinetics and safety of deferasirox in subjects with chronic kidney disease undergoing haemodialysis. <i>Nephrology</i> , 2013, 18, 188-193.	1.6	14
40	Response to Kute: "Facilitators to National Kidney Paired Donation Program"™. <i>Transplant International</i> , 2013, 26, e40-e42.	1.6	0
41	ABO-Incompatible Matching Significantly Enhances Transplant Rates in Kidney Paired Donation. <i>Transplantation</i> , 2013, 96, 821-826.	1.0	52
42	High Transplant Rates of Highly Sensitized Recipients With Virtual Crossmatching in Kidney Paired Donation. <i>Transplantation</i> , 2012, 94, 744-749.	1.0	31
43	Comparison of time on the deceased donor kidney waitlist versus time on the kidney paired donation registry in the Australian program. <i>Transplant International</i> , 2012, 25, 1026-1031.	1.6	18
44	Travel-related disseminated <i>Penicillium marneffei</i> infection in a renal transplant patient. <i>Transplant Infectious Disease</i> , 2012, 14, 434-439.	1.7	42
45	Assessment of reasons for not intensifying antihypertensive treatment in the Taiwanese population. <i>Journal of the Formosan Medical Association</i> , 2011, 110, 768-774.	1.7	0
46	Diagnostic Investigations in Inherited Endocrine Disorders of Sodium Regulation. , 2011, , 210-234.		3
47	Citrate anticoagulation using ACD solution A during long-term haemodialysis. <i>Nephrology</i> , 2011, 16, 396-402.	1.6	15
48	Virtual Crossmatch Approach to Maximize Matching in Paired Kidney Donation. <i>American Journal of Transplantation</i> , 2011, 11, 272-278.	4.7	40
49	Effect of donor-recipient age difference on graft function and survival in live-donor kidney transplantation. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 702-708.	0.7	54
50	Serum Iron Markers Are Inadequate for Guiding Iron Repletion in Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 77-83.	4.5	119
51	Title is missing!. <i>Clinical Therapeutics</i> , 2010, 32, 397.	2.5	1
52	Pentoxifylline improves haemoglobin and interleukin-6 levels in chronic kidney disease. <i>Nephrology</i> , 2010, 15, 344-349.	1.6	25
53	The role of 11 $\beta$ -hydroxysteroid dehydrogenase type 2 in human hypertension. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2010, 1802, 1178-1187.	3.8	138
54	Paired kidney donations to expand the living donor pool: the Western Australian experience. <i>Medical Journal of Australia</i> , 2009, 190, 700-703.	1.7	34

#	ARTICLE	IF	CITATIONS
55	Estimation of glomerular filtration rate: does haemoglobin discriminate between ageing and true CKD?. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 1828-1833.	0.7	13
56	Licorice: a sweet alternative to prevent hyperkalemia in dialysis patients?. <i>Kidney International</i> , 2009, 76, 811-812.	5.2	14
57	The inaccuracy of cystatin C and creatinine-based equations in predicting GFR in orthotopic liver transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 2926-2930.	0.7	26
58	Reasons for therapeutic inertia when managing hypertension in clinical practice in non-Western countries. <i>Journal of Human Hypertension</i> , 2009, 23, 151-159.	2.2	50
59	Results of a meta-analysis comparing the tolerability of lercanidipine and other dihydropyridine calcium channel blockers. <i>Clinical Therapeutics</i> , 2009, 31, 1652-1663.	2.5	43
60	Serum phosphate is an important determinant of corrected serum calcium in end-stage kidney disease. <i>Nephrology</i> , 2009, 14, 383-388.	1.6	27
61	Paired kidney donations to expand the living donor pool. <i>Journal of Nephrology</i> , 2009, 22, 699-707.	2.0	45
62	Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia: a randomized controlled trial. <i>BMC Nephrology</i> , 2008, 9, 8.	1.8	17
63	Decline in native kidney function in liver transplant recipients is not associated with BK virus infection. <i>Liver Transplantation</i> , 2008, 14, 1787-1792.	2.4	18
64	Hip Pain in Renal Transplant Recipients: Symptomatic Gluteus Minimius and Gluteus Medius Tendon Abnormality as an Alternative MRI Diagnosis to Avascular Necrosis. <i>American Journal of Roentgenology</i> , 2007, 188, 515-519.	2.2	29
65	Impaired Protein Stability of 11 $\beta$ -Hydroxysteroid Dehydrogenase Type 2: A Novel Mechanism of Apparent Mineralocorticoid Excess. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 1262-1270.	6.1	42
66	The challenge of renal cystic disease and its association with hypertension, age and abnormal potassium handling. <i>Journal of Hypertension</i> , 2007, 25, 1347-1349.	0.5	0
67	Prescribing angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic kidney disease (Review Article). <i>Nephrology</i> , 2007, 12, 81-89.	1.6	33
68	VENLAFAXINE TO TREAT SEVERE HYPOTENSION. <i>Nephrology</i> , 2007, 12, 622-622.	1.6	1
69	High prevalence of ascorbate deficiency in an Australian peritoneal dialysis population. <i>Nephrology</i> , 2007, 13, 070918212946002-???	1.6	17
70	Apparent Mineralocorticoid Excess: Report of Six New Cases and Extensive Personal Experience. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 3176-3184.	6.1	93
71	A novel mutation in the steroidogenic acute regulatory protein gene promoter leading to reduced promoter activity. <i>Journal of Molecular Endocrinology</i> , 2006, 37, 71-80.	2.5	12
72	Prorenin cryoactivation as a possible cause of normal renin levels in patients with primary aldosteronism. <i>Journal of Hypertension</i> , 2005, 23, 460.	0.5	0

#	ARTICLE	IF	CITATIONS
73	APPARENT ADDISON's DISEASE FOLLOWING ILEOSTOMY. <i>Nephrology</i> , 2005, 10, 537-538.	1.6	1
74	Comparison of continuous and intermittent renal replacement therapy for acute renal failure. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 1630-1637.	0.7	326
75	CYP11B2-CYP11B1 Haplotypes Associated with Decreased 11 $\beta$ -Hydroxylase Activity. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 1220-1225.	3.6	34
76	Salt-sensitive blood pressureâ€”an intermediate phenotype predisposing to diabetic nephropathy?. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 2113-2119.	0.7	10
77	Effects of smoking on renal function in patients with type 1 and type 2 diabetes mellitus. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 2414-2419.	0.7	73
78	Swiss Hypertension and Risk Factor Program (SHARP): Cardiovascular risk factors management in patients with type 2 diabetes in Switzerland. <i>Blood Pressure</i> , 2005, 14, 337-344.	1.5	35
79	Mutation analysis of CYP11B1 and CYP11B2 in patients with increased 18-hydroxycortisol production. <i>Molecular and Cellular Endocrinology</i> , 2004, 214, 167-174.	3.2	14
80	Active renin versus plasma renin activity to define aldosterone-to-renin ratio for primary aldosteronism. <i>Journal of Hypertension</i> , 2004, 22, 377-381.	0.5	93
81	Low prevalence of nonconservative mutations of serum and glucocorticoid-regulated kinase (SGK1) gene in hypertensive and renal patients. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, 2499-2504.	0.7	14
82	Reasons for not intensifying antihypertensive treatment (RIAT). <i>Journal of Hypertension</i> , 2004, 22, 1221-1229.	0.5	61
83	The distinction between Liddle syndrome and apparent mineralocorticoid excess. <i>Pediatric Nephrology</i> , 2003, 18, 607-608.	1.7	2
84	Kidney transplantation in rats: An appraisal of surgical techniques and outcome. <i>Microsurgery</i> , 2003, 23, 387-394.	1.3	37
85	Heme oxygenase-1 attenuates ischemia/reperfusion-induced apoptosis and improves survival in rat renal allografts. <i>Kidney International</i> , 2003, 63, 1564-1573.	5.2	122
86	Long-term calcineurin inhibition and magnesium balance after renal transplantation. <i>Transplant International</i> , 2003, 16, 76-81.	1.6	25
87	Cortisol and the renal handling of electrolytes: role in glucocorticoid-induced hypertension and bone disease. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2003, 17, 575-589.	4.7	54
88	Hypoxia causes downâ€”regulation of 11 $\beta$ -hydroxysteroid dehydrogenase type 2 by induction of Egrâ€”1. <i>FASEB Journal</i> , 2003, 17, 1-22.	0.5	55
89	Angiotensin-Converting Enzyme Inhibition but not Angiotensin II Receptor Blockade Regulates Matrix Metalloproteinase Activity in Patients with Glomerulonephritis. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 2861-2872.	6.1	40
90	Combination treatment with an ETA-receptor blocker and an ACE inhibitor is not superior to the respective monotherapies in attenuating chronic transplant vasculopathy in different aorta allotransplantation rat models. <i>Nephrology Dialysis Transplantation</i> , 2003, 18, 62-69.	0.7	13

#	ARTICLE	IF	CITATIONS
91	A Biallelic Gene Polymorphism of CYP11B2 Predicts Increased Aldosterone to Renin Ratio in Selected Hypertensive Patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 2495-2500.	3.6	51
92	Forms of Mineralocorticoid Hypertension. <i>Vitamins and Hormones</i> , 2003, 66, 113-156.	1.7	19
93	Endothelin 1 Type A Receptor Antagonism Prevents Vascular Dysfunction and Hypertension Induced by 11 $\beta$ -Hydroxysteroid Dehydrogenase Inhibition: Role of Nitric Oxide. <i>Circulation</i> , 2002, 105, e126; author reply e126.	1.6	1
94	Modulation of Renal Calcium Handling by 11 $\beta$ -Hydroxysteroid Dehydrogenase Type 2. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 2540-2546.	6.1	29
95	Additive antiproteinuric effect of combined ACE inhibition and angiotensin II receptor blockade. <i>Journal of Hypertension</i> , 2002, 20, 125-130.	0.5	109
96	Salt-sensitivity of blood pressure and decreased 11 $\beta$ -hydroxysteroid dehydrogenase type 2 activity after renal transplantation <sup>1</sup> . <i>Transplantation</i> , 2002, 74, 66-72.	1.0	16
97	Recipient ras gene variants and renal allograft function <sup>1</sup> . <i>Transplantation</i> , 2002, 73, 960-965.	1.0	17
98	Association of plasminogen activator inhibitor-1 genotype with avascular osteonecrosis in steroid-treated renal allograft recipients <sup>1</sup> . <i>Transplantation</i> , 2002, 74, 1147-1152.	1.0	62
99	Pharmacokinetic-Pharmacodynamic Modelling of Magnesium Plasma Concentration and Blood Pressure in Preeclamptic Women. <i>Clinical Pharmacokinetics</i> , 2002, 41, 1105-1113.	3.5	21
100	Genetics of the mineralocorticoid system in primary hypertension. <i>Current Hypertension Reports</i> , 2002, 4, 18-24.	3.5	23
101	Role of the $\beta$ -adducin genotype on renal disease progression. <i>Kidney International</i> , 2002, 61, 1270-1275.	5.2	33
102	Glycyrrhetic Acid Decreases Plasma Potassium Concentrations in Patients with Anuria. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 191-196.	6.1	43
103	Prophylactic hemodialysis after radiocontrast media in patients with renal insufficiency is potentially harmful. <i>American Journal of Medicine</i> , 2001, 111, 692-698.	1.5	262
104	Genetic polymorphisms of the renin-angiotensin-aldosterone system in end-stage renal disease. <i>Kidney International</i> , 2001, 60, 46-54.	5.2	105
105	Juvenile Hypertension, the Role of Genetically Altered Steroid Metabolism. <i>Hormone Research in Paediatrics</i> , 2001, 55, 213-223.	1.8	16
106	In Vivo 11 $\beta$ -HSD-2 Activity. <i>Hypertension</i> , 2001, 38, 1330-1336.	2.7	127
107	A Mutation in the Cofactor-Binding Domain of 11 $\beta$ -Hydroxysteroid Dehydrogenase Type 2 Associated with Mineralocorticoid Hypertension <sup>1</sup> . <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 1247-1252.	3.6	44
108	A Mutation in the Cofactor-Binding Domain of 11 $\beta$ -Hydroxysteroid Dehydrogenase Type 2 Associated with Mineralocorticoid Hypertension. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 1247-1252.	3.6	33

#	ARTICLE	IF	CITATIONS
109	The role of the 11 $\beta$ -hydroxysteroid dehydrogenase type 2 in human hypertension. <i>Journal of Hypertension</i> , 2000, 18, 241-248.	0.5	79
110	Structural analysis of the 11 $\beta$ -hydroxysteroid dehydrogenase type 2 gene in end-stage renal disease. <i>Kidney International</i> , 2000, 58, 1413-1419.	5.2	25
111	Role of the 11 $\beta$ -hydroxysteroid dehydrogenase type 2 in blood pressure regulation. <i>Kidney International</i> , 2000, 57, 1374-1381.	5.2	84
112	Fatal cardiac arrhythmia after infusion of dimethyl sulfoxide-cryopreserved hematopoietic stem cells in a patient with severe primary cardiac amyloidosis and end-stage renal failure. <i>Annals of Hematology</i> , 2000, 79, 523-526.	1.8	122
113	Pastis and hypertension—what is the molecular basis?. <i>Nephrology Dialysis Transplantation</i> , 2000, 15, 1512-1514.	0.7	6
114	Molecular Basis of Human Salt Sensitivity: The Role of the 11 $\beta$ -Hydroxysteroid Dehydrogenase Type 2*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 3745-3749.	3.6	134
115	Hypovolemia contributes to the pathogenesis of orthostatic hypotension in patients with diabetes mellitus. <i>American Journal of Medicine</i> , 1999, 106, 50-58.	1.5	20
116	Permanently reduced plasma ionized magnesium among renal transplant recipients on cyclosporine. <i>Transplant International</i> , 1999, 12, 244-249.	1.6	15
117	The Codon 213 of the 11 $\beta$ -Hydroxysteroid Dehydrogenase Type 2 Gene Is a Hot Spot for Mutations in Apparent Mineralocorticoid Excess1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 4391-4393.	3.6	16
118	A genetic defect resulting in mild low-renin hypertension. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 10200-10205.	7.1	136
119	Endothelin-1 infusion inhibits plasma insulin responsiveness in normal men. <i>Journal of Hypertension</i> , 1998, 16, 1279-1284.	0.5	25
120	A New Polymorphic Restriction Site in the Human 11 $\beta$ -Hydroxysteroid Dehydrogenase Type 2 Gene. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 1814-1814.	3.6	40
121	Oxoreductase and Dehydrogenase Activities of the Human and Rat 11 $\beta$ -Hydroxysteroid Dehydrogenase Type 2 Enzyme*. <i>Endocrinology</i> , 1997, 138, 2948-2952.	2.8	45
122	Truncation of the N- and C-terminal regions of the human 11 $\beta$ -hydroxysteroid dehydrogenase type 2 enzyme and effects on solubility and bidirectional enzyme activity. <i>Molecular and Cellular Endocrinology</i> , 1997, 131, 173-182.	3.2	25
123	Oxoreductase and Dehydrogenase Activities of the Human and Rat 11 $\beta$ -Hydroxysteroid Dehydrogenase Type 2 Enzyme. <i>Endocrinology</i> , 1997, 138, 2948-2952.	2.8	18
124	The 11 $\beta$ -hydroxysteroid dehydrogenase type II enzyme: Biochemical consequences of the congenital R337C mutation. <i>Steroids</i> , 1996, 61, 197-200.	1.8	25
125	Point mutations abolish 11 $\beta$ -hydroxysteroid dehydrogenase type II activity in three families with the congenital syndrome of apparent mineralocorticoid excess. <i>Molecular and Cellular Endocrinology</i> , 1996, 119, 21-24.	3.2	56
126	Rat 11 $\beta$ -hydroxysteroid dehydrogenase type 2 enzyme is expressed at low levels in the placenta and is modulated by adrenal steroids in the kidney. <i>Molecular and Cellular Endocrinology</i> , 1996, 120, 67-75.	3.2	44



#	ARTICLE	IF	CITATIONS
127	Reduced Plasma Cyclic GMP But Normal Renal Responses to Atrial Natriuretic Factor in Pre-Hypertension. <i>Blood Pressure</i> , 1996, 5, 16-26.	1.5	10
128	Lack of effect of long-term amlodipine on insulin sensitivity and plasma insulin in obese patients with essential hypertension. <i>European Journal of Clinical Pharmacology</i> , 1993, 44, 457-462.	1.9	33
129	Insulin sensitivity and body fat distribution in normotensive offspring of hypertensive parents. <i>Lancet, The</i> , 1993, 341, 327-331.	13.7	113
130	Serum Lipoproteins During Treatment with Antihypertensive Drugs. <i>Journal of Cardiovascular Pharmacology</i> , 1993, 22, 98-105.	1.9	33
131	Enhanced Blood Pressure Response to Mineralocorticoid Stimulation in Normotensive Members of Hypertensive Families. <i>Blood Pressure</i> , 1992, 1, 86-91.	1.5	8
132	Left ventricular structure and determinants in normotensive offspring of essential hypertensive parents. <i>Journal of Hypertension</i> , 1992, 10, 1257-1264.	0.5	13
133	Swiss Hypertension Treatment Programme with Verapamil and/or Enalapril in Diabetic Patients. <i>Drugs</i> , 1992, 44, 74-84.	10.9	5
134	Insulin sensitivity in normotensive subjects during angiotensin converting enzyme inhibition with fosinopril. <i>European Journal of Clinical Pharmacology</i> , 1992, 42, 275-80.	1.9	31
135	Effect of prolonged bicarbonate administration on plasma potassium in terminal renal failure. <i>Kidney International</i> , 1992, 41, 369-374.	5.2	97
136	Altered insulin sensitivity, hyperinsulinemia, and dyslipidemia in individuals with a hypertensive parent. <i>American Journal of Medicine</i> , 1991, 91, 589-596.	1.5	209
137	Postsynaptic $\hat{\pm}$ 1-Blockade with Terazosin Does Not Modify Insulin Sensitivity in Nonobese Normotensive Subjects. <i>Journal of Cardiovascular Pharmacology</i> , 1991, 18, 106-110.	1.9	10
138	Atrial natriuretic factor after cardiac surgery with cardiopulmonary bypass in children. <i>Critical Care Medicine</i> , 1991, 19, 1497-1502.	0.9	6
139	Abnormalities of Insulin and Lipid Metabolism in Milan Hypertensive Rats. <i>American Journal of Hypertension</i> , 1991, 4, 773-775.	2.0	45
140	Antihypertensive agents, serum lipoproteins and glucose metabolism. <i>American Journal of Cardiology</i> , 1991, 67, B26-B35.	1.6	68
141	Reproducibility of insulin sensitivity measured by the minimal model method. <i>Diabetologia</i> , 1991, 34, 527-530.	6.3	64
142	Unaltered insulin sensitivity during calcium channel blockade with amlodipine. <i>European Journal of Clinical Pharmacology</i> , 1991, 41, 109-13.	1.9	19
143	Central Role of Sodium in Hypertension in Diabetic Subjects. <i>Diabetes Care</i> , 1991, 14, 220-232.	8.6	99
144	Antihypertensive Therapy With Ca <sup>2+</sup> : Antagonist Verapamil and/or ACE Inhibitor Enalapril in NIDDM Patients. <i>Diabetes Care</i> , 1991, 14, 911-914.	8.6	34

#	ARTICLE	IF	CITATIONS
145	Insulin, insulin sensitivity and hypertension. Journal of Hypertension, 1990, 8, 491-500.	0.5	152
146	Dysregulation of Atrial Natriuretic Factor in Hypertension-Prone Man <sup>*</sup> . Journal of Clinical Endocrinology and Metabolism, 1990, 71, 944-951.	3.6	41
147	Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature, 0, , .	27.8	101